Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.44 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1383998 | 0.89 | MAPK14 (0.47) | MAPK14CSNK1DCSNK1ECSNK1A1MAPK13 | |
| SCHEMBL1384274 | 0.89 | MAPK14 (0.46) | MAPK14CSNK1DCSNK1ECSNK1A1MAPK13 | |
| SCHEMBL2929628 | 0.87 | MAPK14 (0.49) | MAPK14CSNK1DCSNK1ECSNK1A1MAPK13 | |
| SCHEMBL2930273 | 0.87 | MAPK14 (0.48) | MAPK14CSNK1DCSNK1ECSNK1A1MAPK13 | |
| SCHEMBL2929338 | 0.87 | MAPK14 (0.44) | MAPK14CSNK1DCSNK1ECSNK1A1MAPK13 | |
| SCHEMBL2926483 | 0.87 | MAPK14 (0.48) | MAPK14CSNK1DCSNK1ECSNK1A1MAPK13 | |
| SCHEMBL2929455 | 0.87 | MAPK14 (0.48) | MAPK14CSNK1DCSNK1ECSNK1A1MAPK13 | |
| SCHEMBL2931774 | 0.86 | MAPK14 (0.44) | MAPK14CSNK1DCSNK1ECSNK1A1MAPK13 | |
| SCHEMBL1384271 | 0.86 | MAPK14 (0.45) | MAPK14CSNK1DCSNK1ECSNK1A1MAPK13 | |
| SCHEMBL1384359 | 0.86 | MAPK14 (0.47) | MAPK14CSNK1DCSNK1ECSNK1A1MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536194-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2013-09-17 | — | — | US | disclosed |
| EP-1611131-B1 | PYRAZOLOPYRIDINE DERIVATES | PALAU PHARMA SA (ES) | 2010-09-15 | — | — | EP | disclosed |
| US-20090286983-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | disclosed |
| US-20090005377-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-01-01 | — | — | US | disclosed |
| US-7468376-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2008-12-23 | — | — | US | disclosed |
| US-20060167040-A1 | Pyrazolopyridine derivates | J. URIACH Y COMPANIA S.A. (ES) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167040-A1 | Pyrazolopyridine derivates | MAPK1, MAP4K2, MAP4K3 | MAPK14 34/4885CSNK1D 75/4885CSNK1E 235/4885 |
| US-20090286983-A1 | Pyrazolopyridine Derivates | MAPK1, MAPK4, MAP4K2 | MAPK14 33/4885CSNK1D 60/4885CSNK1E 165/4885 |
| US-20090005377-A1 | Pyrazolopyridine Derivates | MAPK1, MAPK4, MAP4K2 | MAPK14 33/4885CSNK1D 60/4885CSNK1E 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.